Hitachi Chemical Co. America, Ltd.’s Acquisition of Caladrius Biosciences, Inc.’s TPC

Paul Hastings LLP represented Caladrius Biosciences, Inc., (CLBS) a NASDAQ-listed clinical stage development company with a cell therapy pipeline focused on immune modulation and select cardiovascular…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now